Discovery of antimycobacterial spiro-piperidin-4-ones: An atom economic, stereoselective synthesis, and biological intervention

Journal of Medicinal Chemistry

Volumn 51, Issue 18, 2008, Pages 5731-5735

  Kumar, Raju Ranjith ^a   Perumal, Subbu ^a   Senthilkumar, Palaniappan ^b   Yogeeswari, Perumal ^b   Sriram, Dharmarajan ^b  

^a MADURAI KAMARAJ UNIVERSITY   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 5 PHENYLPYRROLO(SPIRO[2,3'']OXINDOLE)SPIRO[3,3'] 1' METHYL 5' (4 FLUOROPHENYLMETHYLIDENE)PIPERIDIN 4' ONE; ANTIMYCOBACTERIAL AGENT; CIPROFLOXACIN; ISONIAZID; PIPERIDINE DERIVATIVE; SPIRO COMPOUND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; LUNG; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SPLEEN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; VERO CELL;

ANTITUBERCULAR AGENTS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PIPERIDINES; STEREOISOMERISM;

EID: 52449097257     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800545k     Document Type: Article

References (27)

1. World Health Organization, Tuberculosis Fact Sheet 2006, http://www.who.int/tb/publications/2006/tb_factsheet_2006_1_en.pdf.
2. Granich, R.; Wares, F.; Suvanand, S.; Chauhan, L. S. Tuberculosis control in India. Lancet Infect. Dis. 2003, 3, 535.
3. Sharma, D. C. India makes poor tuberculosis progress in 2002. Lancet Infect. Dis. 2003, 5, 265.
4. Bass, J. B.; Farer, L. S.; Hopewell, P. C.; O'Brien, R.; Jacobs, R. F.; Ruben, F.; Snider, D. E.; Thornton, G. Treatment of tuberculosis and tuberculosis infection in aduits and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am. J. Respir. Crit. Care Med. 1994, 149, 1359-1374.
5. Bhowruth, V.; Dover, L. G.; Besra, G. S. Tuberculosis Chemotherapy: Recent Developments and Future Perspectives. Prog. Med. Chem. 2007, 45, 169-203.
6. Rattan, A.; Kalia, A.; Ahmad, N. Multidrug-Resistant Mycobacterium tuberculosis: Molecular Prospectives. Emerg. Infect. Dis. 1998, 4, 195-209.
7. O'Brien, R. J.; Nunn, P. P. The Need for New Drugs against Tuberculosis. Obstacles, Opportunities, and Next Steps. Am. J. Respir. Crit. Care Med. 2001, 163, 1055-1058.
8. (a) Watson, A. A.; Fleet, G. W. J.; Asano, N.; Molyneux, R. J.; Nash, R. J. Polyhydroxylated alkaloids-natural occurrence and therapeutic applications. Phytochemistry 2001, 56, 265-295.
9. (b) O'Hagan, D. Pyrrole, pyrrolidine pyridine, piperidine, azepine and tropane alkaloids. Nat. Prod. Rep. 1997, 14, 637-651.
10. (c) Horri, S.; Fukase, H.; Matsuo, T.; Kameda, Y.; Asano, N.; Matsui, K. Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents. J. Med. Chem. 1986, 29, 1038-1046.
11. (d) Spearman, M. A.; Jamieson, J. C.; Wright, J. A. Studies on the effect of glycoprotein processing inhibitors on fusion of L6 myoblast cell lines. Exp. Cell Res. 1987, 168, 116-126.
12. (e) Karpas, A.; Fleet, G. W. J.; Dwek, R. A.; Petursson, S.; Mamgoong, S. K.; Ramsden, N. G.; Jacob, G. S.; Rademacher, T. W. Aminosugar Derivatives as Potential Anti-Human Immunodeficiency Virus Agents. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 9229-9233.
13. (a) Liddell, J R. Pyrrolidine alkaloids. Nat. Prod. Rep. 1998, 15, 363-370.
14. (b) Michael, J. P. Indolizidine and quinolizidine alkaloids. Nat. Prod. Rep. 1997, 14, 619-636.
15. (a) Chande, M. S.; Verma, R. S.; Barve, P. A.; Khanwelkar, R. R. Facile synthesis of active antitubercular, cytotoxic and antibacterial agents: a Michael addition approach. Eur. J. Med. Chem. 2005, 40, 1143-1148.
16. (b) Dandia, A.; Sati, M.; Arya, K.; Sharma, R.; Loupy, A. Facile One-Pot Microwave Induced Solvent-Free Synthesis and Antifungal, Antitubercular Screening of Spiro[1,5]-Benzothiazepin-2,3′[3′H]indol- 2[1′H]-ones. Chem. Pharm. Bull. 2003, 51, 1137-1141.
17. Sriram, D.; Yogeeswari, P.; Madhu, K. Synthesis and in vitro antitubercular activity of some 1-[(4-sub)phenyl]-3-(4-{1-[(pyridine-4-carbonyl) hydrazono]ethyl}phenyl) thiourea. Bioorg. Med. Chem. Lett. 2006, 16, 876-878.
18. Biava, M.; Porretta, G. C.; Poce, G.; Supino, S.; Deidda, D.; Pompei, R.; Molicotti, P.; Manetti, F.; Botta, M. Antimycobacterial Agents. Novel Diarylpyrrole Derivatives of BM212 Endowed with High Activity toward Mycobacterium tuberculosis and Low Cytotoxicity. J. Med. Chem. 2006, 49, 4946-4952.
19. 1-nicotinoyl-3-(4′-hydroxy-3′-methylphenyl)-5-[(sub) phenyl]-2-pyrazolines. Bioorg. Med. Chem. Lett. 2006, 16, 3947-3949.
20. Ranjith Kumar, R.; Perumal, S.; Senthilkumar, P.; Yogeeswari, P.; Sriram, D. A highly atom economic, chemo-, regio- and stereoselective synthesis, and discovery of spiro-pyrido-pyrrolizines and pyrrolidines as antimycobacterial agents. Tetrahedron 2008, 64, 2962-2971.
21. Ranjith Kumar, R.; Perumal, S.; Senthilkumar, P.; Yogeeswari, P.; Sriram, D. An atom efficient, solvent-free, green synthesis and antimycobacterial evaluation of 2-amino-6-methyl-4-aryl-8-[(E)-aryl-methylidene]-5,6,7,8- tetrahydro-4H-pyrano[3,2-c]pyridine-3-carbonitriles. Bioorg. Med. Chem. Lett. 2007, 17, 6459-6462.
22. Crystallographic data (excluding structure factors) for 3a in this article have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 686497. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44 (0) 1223 336033 or e-mail: deposit@ccdc.cam.ac.uk). (b) Kumar, V. V.; Gayathri, D.; Velmurugan, D.; Ravikumar, K.; Sridhar, G. Acta. Cryst. 2007, 63, 2211-2212.
23. Ranjith Kumar, R.; Perumal, S. Sacrificial azomethine ylide cycloaddition controlled chemoselective nitrile oxide cycloaddition to 1-methyl-3,5- bis[(E)-arylmethylidene]tetrahydro-4(1H)-pyridinones: formation of mono-spiro-isoxazolines. Tetrahedron 2007, 63, 12220-12231.
24. Crystallographic data (excluding structure factors) for 5g in this article have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 686496. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44 (0) 1223 336033 or e-mail: deposit@ccdc.cam.ac.uk).H
25. National Committee for Clinical Laboratory Standards. Antimycobacterial susceptibility testing for Mycobacterium tuberculosis; Proposed Standard M24-T; National Committee for Clinical Laboratory Standards: Villanova, PA, 1995.
26. Sridhar, G.; Raghunathan, R. Rapid Access for the Synthesis of 1-N-Methyl-spiro[2. 3′]oxindole-spiro[3.7″](3″-aryl)- 5″-methyl-3″,3a″,4″,5″,6″, 7″-hexahydro-2H-pyrazolo[4,3-c]pyridine-4-aryl-pyrrolidines Through Sequential 1,3-Dipolar Cycloaddition and Annulation. Synth. Commun. 2006, 36, 21-29.
27. Gundersen, L. L.; Nissen-Meyer, J.; Spilsberg, B. Synthesis and Antimycobacterial Activity of 6-Arylpurines: The Requirements for the N-9 Substituent in Active Antimycobacterial Purines. J. Med. Chem. 2002, 45, 1383-1386.